Patent US5071879A successfully refreshed from Google Patents.
US5071879A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Systemic antiviral treatment
Assignee: Avanir Pharmaceuticals Inc
•
Filing: 1989-11-02
•
Granted: 1991-12-10
•
Expires: 2009-11-02
Abstract
Abstract Systemic antiviral treatment using a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 20 to 26, preferably 22 to 26, carbons in the chain in physiologically compatible compositions for injection or trans-mucus membrane introduction into humans and other animals is disclosed.
Inventors
- 👤 David H. Katz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 17:05
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/045; A61P; A61P17/00; A61P31/00; A61P31/04; A61P31/12
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
45 words
A method of treating or preventing disease in humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 2
Independent Claim
45 words
A method of treating or preventing disease in humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 3
Independent Claim
48 words
A method of treating or preventing disease in humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated by intramuscular injection a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 4
Independent Claim
48 words
A method of treating or preventing disease in humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated by intramuscular injection a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 5
Independent Claim
49 words
A method of treating or preventing disease in humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated by transmucus membranal penetration a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 6
Independent Claim
49 words
A method of treating or preventing disease in humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated by transmucus membranal penetration a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 7
Independent Claim
45 words
A method of treating or preventing disease in humans or other animals, comprising introducing into the human or other animal to be treated by transdermal penetration of a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 8
Independent Claim
45 words
A method of treating or preventing disease in humans or other animals, comprising introducing into the human or other animal to be treated by transdermal penetration of a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 9
Independent Claim
46 words
A method of preventing or inhibiting virus infection of humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 10
Independent Claim
46 words
A method of preventing or inhibiting virus infection of humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 11
Independent Claim
49 words
A method of preventing or inhibiting virus infection of humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated by intramuscular injection a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 12
Independent Claim
49 words
A method of preventing or inhibiting virus infection of humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated by intramuscular injection a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 13
Independent Claim
50 words
A method of preventing or inhibiting virus infection of humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated by transmucus membrane penetration a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 14
Independent Claim
50 words
A method of preventing or inhibiting virus infection of humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated by transmucus membrane penetration a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 15
Independent Claim
49 words
A method of preventing or inhibiting virus infection of humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated by transdermal penetration a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 16
Independent Claim
49 words
A method of preventing or inhibiting virus infection of humans or other animals, comprising introducing into the circulatory system of the human or other animal to be treated by transdermal penetration a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier.
Claim 17
Dependent Claim
40 words
A physiologically compatible solution suitable for injection into humans or other animals to prevent or treat disease in such humans or other animals consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible injectable carrier.
Claim 18
Dependent Claim
40 words
A physiologically compatible solution suitable for injection into humans or other animals to prevent or treat disease in such humans or other animals consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible injectable carrier.
Claim 19
Dependent Claim
31 words
A physiologically compatible transdermal medication for introduction through the mucous membranes into humans or other animals consisting essentially of at least one C-20 to C-26 aliphatic alcohol and a penetration enhancer.
Claim 20
Dependent Claim
31 words
A physiologically compatible transdermal medication for introduction through the mucous membranes into humans or other animals consisting essentially of at least one C-20 to C-26 aliphatic alcohol and a penetration enhancer.
Claim 21
Dependent Claim
18 words
The method of claim 1 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier.
Claim 22
Dependent Claim
18 words
The method of claim 2 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier.
Claim 23
Dependent Claim
18 words
The method of claim 3 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier.
Claim 24
Dependent Claim
18 words
The method of claim 4 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier.
Claim 25
Dependent Claim
18 words
The method of claim 5 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier.
Claim 26
Dependent Claim
18 words
The method of claim 6 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier.
Claim 27
Dependent Claim
18 words
The method of claim 7 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier.
Claim 28
Dependent Claim
18 words
The method of claim 8 wherein composition consists essentially of C-22 aliphatic alcohol in a physiologically compatible carrier.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-12-09 | 1995-06-10 | 1995-12-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-12-09 | 1999-06-10 | 1999-12-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-12-09 | 2003-06-10 | 2003-12-10 | $7700.00 | Window Closed / Lapsed |